 This multicenter, randomized, parallel groups, placebo-study is designed for subjects with primary hypercholesterolemia plasma LDL-C concentrations between 2.6 mmolL 100 mgdL to 4.1 mmolL 160 mgdL and triglyceride concentrations of 3.99 mmolL 350 mgdL and coronary heart disease who are currently being treated with atorvastatin 10 mg and would benefit from additional reduction in LDL-C. 